Status:
COMPLETED
Comparison of Oral Brivaracetam Versus Levetiracetam as Monotherapy in Epilepsy
Lead Sponsor:
RESnTEC, Institute of Research
Conditions:
Epilepsy
Eligibility:
All Genders
1-14 years
Phase:
NA
Brief Summary
Despite increasing clinical use of both agents, there is a paucity of head-to-head comparative data on the safety and efficacy of brivaracetam versus levetiracetam as initial monotherapy in children. ...
Detailed Description
Most existing studies have focused on adjunctive use or refractory epilepsy, while evidence in treatment-naïve pediatric populations remains sparse. Addressing this gap is critical, as early and effec...
Eligibility Criteria
Inclusion
- Children of either gender
- Aged 1 month to 14 years
- With a clinical diagnosis of newly diagnosed epilepsy
Exclusion
- History of prior use of long-term antiseizure medications
- Evidence of progressive neurological disease
- Metabolic abnormalities
- Structural brain malformations
- Incompatible with monotherapy
- Severe systemic comorbidities
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2025
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT07163585
Start Date
August 1 2024
End Date
July 31 2025
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Children's Hospital and Institute of Child Health
Multan, Punjab Province, Pakistan, 66000